Enhancement of 5-fluorouracil-induced cytotoxicity by leucovorin in 5-fluorouracil-resistant gastric cancer cells with upregulated expression of thymidylate synthase.
Enhancement of 5-fluorouracil-induced cytotoxicity by leucovorin in 5-fluorouracil-resistant gastric cancer cells with upregulated expression of thymidylate synthase.
复制标题
DOI:
10.1007/s10120-013-0249-7
复制
发表时间:
2014-01
期刊:
影响因子:
7.4
通讯作者:
Hayashi, Kazuhiko
中科院分区:
文献类型:
--
作者:
Nakamura, Ayako;Nakajima, Go;Okuyama, Ryuji;Kuramochi, Hidekazu;Kondoh, Yurin;Kanemura, Toshinori;Takechi, Teiji;Yamamoto, Masakazu;Hayashi, Kazuhiko
Elucidation of the mechanisms by which gastric cancer cells acquire resistance to 5-fluorouracil (5FU) may provide important clues to the development of effective chemotherapy for 5FU-resistant gastric cancer Four 5FU-resistant cell lines (MKN45/5FU, MKN74/5FU, NCI-N87/5FU, and KATOIII/5FU) were established by continuous exposure of the cells to progressively increasing concentrations of 5FU for about 1 year. Then, mRNA expression levels of four genes associated with 5FU metabolism, i.e., thymidylate synthase (TS), dihydropyrimidine dehydrogenase, thymidine phosphorylase, and orotate phosphoribosyltransferase, were quantitatively evaluated by real-time reverse transcriptase-polymerase chain reaction. In addition, TS protein expression was measured by Western blot analysis. As compared with the parent cell lines, the 5FU-resistant cell lines showed 3.8- to 11.6-fold higher resistance to 5FU, as well as 1.9- to 3.5-fold higher TS mRNA expression and 1.6- to 7.1-fold higher TS protein expression. In contrast, the expressions of other genes did not differ significantly among the cell lines. The cytotoxicity of 5FU was enhanced 2.3- to 2.8 fold by leucovorin (LV) against three of the four 5FU-resistant cell lines. Collectively, LV enhanced the cytotoxicity of 5FU not only against the parent gastric cancer cell lines, but also against the 5FU-resistant cell lines, even those with elevated TS expression levels. These results suggest that clinical studies of a combination of 5FU and LV are warranted in patients who have recurrent gastric cancer after 5FU-based therapy.
登录
查看更多内容
影响因子:
8.4
作者:
Fukushima, M;Fujioka, A;Takechi, T
通讯作者:
Takechi, T
影响因子:
11.2
作者:
Mizuarai, Shinji;Yamanaka, Kazunori;Kotani, Hidehito
通讯作者:
Kotani, Hidehito
影响因子:
3.7
作者:
Kim HP;Yoon YK;Kim JW;Han SW;Hur HS;Park J;Lee JH;Oh DY;Im SA;Bang YJ;Kim TY
通讯作者:
Kim TY
DOI:
10.1111/j.1349-7006.2000.tb00866.x
发表时间:
2000-01
期刊:
Japanese journal of cancer research : Gann
影响因子:
--
作者:
Ishikawa Y;Kubota T;Otani Y;Watanabe M;Teramoto T;Kumai K;Takechi T;Okabe H;Fukushima M;Kitajima M
通讯作者:
Kitajima M
DOI:
10.1016/j.bbrc.2007.11.043
发表时间:
2008-01-25
影响因子:
3.1
作者:
Sakamoto, Etsuko;Tsukioka, Sayaka;Oka, Tatsuzo
通讯作者:
Oka, Tatsuzo